TwinStrand Biosciences - TwinStrand Biosciences

TwinStrand’s DuplexSeq™ Mutagenesis Assay is now owned and operated by Scantox. Learn more about DuplexSeq™ Mutagenesis Assays at Scantox.

Read more about the acquisition in the news.

Identify aml-related mutations with 100-fold higher resolution

Highest Resolution Next-Generation Sequencing (NGS)

TwinStrand Duplex Sequencing® technology reduces your sequencing error rates from 1-in-100 to 1-in-10 million, revealing data otherwise hidden. Using a combination of proprietary biochemistry and cloud-based informatics, the limitations of standard sequencing are overcome by independently tracking both strands of individual DNA molecules and comparing the results to eliminate errors.

Detect Rare Variants Like Never Before

Whether you are studying measurable residual disease, mutation signatures, cellular immunotherapy monitoring, or any low-level variants, you need accuracy beyond standard NGS. TwinStrand Duplex Sequencing reveals important low frequency variants that aren’t detectable by other methods.

TwinStrand Duplex Sequencing technology eliminates background errors for a >10,000-fold increase in sensitivity over standard NGS

By sequencing both strands of DNA an error-corrected consensus sequence is created for greater specificity that reveals ultra-low frequency variants with a >10,000-fold increase in sensitivity over standard NGS.

The true variant (dark purple) can be hiding in the background of standard NGS (light purple).

The true variant easily detected with Duplex Sequencing.